Abstract
Relationship between activity and structure of the selected 4-chloro-2-mercapto-5-methylbenzensulfonamide derivatives with their potential anticancer activity was studied. Lipophilicity was determined using two distinct chromatographic methods. Moreover, geometry of studied compounds was optimized with the help of HyperChem software to obtain some molecular descriptors. Reversed-phase and micellar liquid chromatography lipophilicity parameters together with theoretically calculated parameters were used to study the relationship between structure and activity. Principal component analysis performed firstly on activity data and secondly on molecular parameters revealed similar results, which allowed us to divide studied set of compounds into three distinct clusters differing in both structure and activity. Moreover, stepwise regression analysis led to statistically significant equation describing potential anticancer activity of studied derivatives based on nuclear energy and log P (partition coefficient) of compounds.
Keywords: Antitumor agents, 4-Chloro-2-mercapto-5-methylbenzensulfonamide derivatives, Lipophilicity, Principal component analysis (PCA), Quantitative structure-activity relationship (QSAR), Stepwise regression
Medicinal Chemistry
Title:Antitumor Activity of Novel Benzensulfonamide Derivatives in View of their Physiochemical Properties Searched by Principal Component Analysis
Volume: 9 Issue: 4
Author(s): Mariusz Belka, Jaroslaw Slawinski, Lucyna Konieczna, Piotr Kawczak, Tomasz Ciesielski and Tomasz Baczek
Affiliation:
Keywords: Antitumor agents, 4-Chloro-2-mercapto-5-methylbenzensulfonamide derivatives, Lipophilicity, Principal component analysis (PCA), Quantitative structure-activity relationship (QSAR), Stepwise regression
Abstract: Relationship between activity and structure of the selected 4-chloro-2-mercapto-5-methylbenzensulfonamide derivatives with their potential anticancer activity was studied. Lipophilicity was determined using two distinct chromatographic methods. Moreover, geometry of studied compounds was optimized with the help of HyperChem software to obtain some molecular descriptors. Reversed-phase and micellar liquid chromatography lipophilicity parameters together with theoretically calculated parameters were used to study the relationship between structure and activity. Principal component analysis performed firstly on activity data and secondly on molecular parameters revealed similar results, which allowed us to divide studied set of compounds into three distinct clusters differing in both structure and activity. Moreover, stepwise regression analysis led to statistically significant equation describing potential anticancer activity of studied derivatives based on nuclear energy and log P (partition coefficient) of compounds.
Export Options
About this article
Cite this article as:
Belka Mariusz, Slawinski Jaroslaw, Konieczna Lucyna, Kawczak Piotr, Ciesielski Tomasz and Baczek Tomasz, Antitumor Activity of Novel Benzensulfonamide Derivatives in View of their Physiochemical Properties Searched by Principal Component Analysis, Medicinal Chemistry 2013; 9 (4) . https://dx.doi.org/10.2174/1573406411309040005
DOI https://dx.doi.org/10.2174/1573406411309040005 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents on MicroRNA-Induced Pluripotent Stem Cell Generation
Recent Patents on Regenerative Medicine Deregulation of PI3K/Akt/mTOR Signaling Pathways by Isoflavones and its Implication in Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications
Current Cancer Drug Targets Medicinal Compound Celastrol As a Potential Clinical Anticancer Drug: Lessons Learned From Preclinical Studies
Clinical Cancer Drugs The Many Faces of MTA3 Protein in Normal Development and Cancers
Current Protein & Peptide Science The 9p21 Locus and its Potential Role in Atherosclerosis Susceptibility; Molecular Mechanisms and Clinical Implications
Current Pharmaceutical Design Progress in Immunotherapy of Head and Neck Squamous Cell Carcinoma
Current Molecular Pharmacology Local Gene Delivery for Cancer Therapy
Current Gene Therapy The Use of Vitamin D in Respiratory Diseases
Current Respiratory Medicine Reviews The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients
Current Pharmaceutical Biotechnology Targeted Pathways in Breast Cancer: Molecular and Protein Markers Guiding Therapeutic Decisions
Current Molecular Pharmacology PI3K/Akt/JNK/c-Jun Signaling Pathway is a Mediator for Arsenite- Induced Cyclin D1 Expression and Cell Growth in Human Bronchial Epithelial Cells
Current Cancer Drug Targets Targeting the SUMO E2 Conjugating Enzyme Ubc9 Interaction for Anti-Cancer Drug Design
Anti-Cancer Agents in Medicinal Chemistry Past, Present, and Future of Targeting Ras for Cancer Therapies
Mini-Reviews in Medicinal Chemistry Gestational Trophoblastic Neoplasia, an Ancient Disease: New Light and Potential Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Neurogenesis in Alzheimers Disease: A Realistic Alternative to Neuronal Degeneration?
Current Signal Transduction Therapy Imaging Endogenous Neurotransmitters In Vivo with Positron Emission Tomography Displacement Studies
Current Psychopharmacology Novel Therapeutic Approaches to Regulate Human Dihydrofolate Reductase Activity and Expression
Current Enzyme Inhibition Interleukin-6/interleukin-6 Receptor Pathway as a New Therapy Target in Epithelial Ovarian Cancer
Current Pharmaceutical Design Transglutaminase-Mediated Activation of Nuclear Transcription Factor-κB in Cancer Cells: A New Therapeutic Opportunity
Current Cancer Drug Targets